Our Technology for HBV

Gene-Modified Cell Therapies for HBV


Despite the availability of an effective vaccine, Hepatitis B Virus (HBV) is the world’s most common serious liver infection. It is the leading cause of liver cancer and the second leading cause of cancer deaths in the world. Two billion people have been infected with HBV, 257 million people have chronic infection, and nearly one million die every year.

Current efforts to develop a novel treatment or cure largely focus on approaches to deplete the pool of a certain type of HBV DNA. Enochian has collaborated with Seraph Research Institute to develop an innovative approach to co-opt HBV polymerase to induce the death of liver cells infected with the virus.

The preliminary in vivo and in vitro work was presented at the biannual HEP DART meeting in December of 2019, where it was selected as one of the best new therapies/novel strategies.

Data confirming and expanding the studies presented at the HEP DART have been presented at the annual meeting of the American Society of Gene and Cell Therapy in May 2020.

Hijacking HBV Pol to Selectively Induce Apoptosis in Infected Hepatocytes In Vivo: A Novel Approach for a Potential Treatment or Cure

Poster Presentation Link Here Slide Presentation Link Here